Susceptibility to Melaleuca alternifolia (tea tree) oil of yeasts isolated from the mouths of patients with advanced cancer

Oral Oncology

Volumn 42, Issue 5, 2006, Pages 487-492

  Bagg, Jeremy ^a   Jackson, Margaret S ^a   Petrina Sweeney, M ^a   Ramage, Gordon ^b   Davies, Andrew N ^c  

^a GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Cancer; Oral infection; Tea tree oil; Yeasts

Indexed keywords

TEA TREE OIL;

ADVANCED CANCER; ANALYTIC METHOD; ARTICLE; DILUTION; DRUG SENSITIVITY; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MOUTH CANCER; MOUTH INFECTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; YEAST;

ANTI-INFECTIVE AGENTS, LOCAL; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOCOMPROMISED HOST; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PALLIATIVE CARE; PHYTOTHERAPY; TEA TREE OIL;

EID: 33646154225     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2005.10.002     Document Type: Article

References (37)

1. Aldred M.J., Addy M., Bagg J., and Finlay I. Oral health in the terminally ill: a cross-sectional pilot survey. Spec Care Dentist 11 2 (1991) 59-62
2. Clarke J.G.M., Wilson J., Von Haacke N.P., and Milne L.J.R. Oral candidiasis in terminal illness. Health Bull (Edin) 45 5 (1987) 268-271
3. Finlay I.G. Oral symptoms and candida in the terminally ill. Brit Med J 292 (1986) 592-593
4. Davies A.N., Brailsford S., Broadley K., and Beighton D. Oral yeast carriage in patients with advanced cancer. Oral Microbiol Immunol 17 2 (2002) 79-84
5. Bagg J., Sweeney M.P., Lewis M.A.O., et al. High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer. Palliative Med 17 6 (2003) 477-481
6. Bagg J., Sweeney M.P., Davies A.N., Jackson M.S., and Brailsford S. Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer. J Med Microbiol 54 10 (2005) 959-964
7. Davies A., and Finlay I. Oral care in advanced disease (2005), Oxford University Press, Oxford
8. Carson C.F., and Riley T.V. Antimicrobial activity of the essential oil of Melaleuca alternifolia. Lett Appl Microbiol 16 1 (1993) 49-55
9. Brophy J.J., Davies N.W., Southwell I.A., Stiff I.A., and Williams I.R. Gas chromatographic quality control for oil of Melaleuca terpinen-4-ol (Australian tea tree). J Agric Food Chem 37 5 (1989) 1330-1335
10. Brand C., Grimbaldeston M.A., Gamble J.R., Drew J., Finlay-Jones J.J., and Hart P.H. Tea tree oil reduces the swelling associated with the efferent phase of a contact hypersensitivity response. Inflamm Res 51 5 (2002) 236-244
11. Koh K.J., Pearce A.L., Marshman G., Finlay-Jones J.J., and Hart P.H. Tea tree oil reduces histamine-induced skin inflammation. Brit J Dermatol 147 6 (2002) 1212-1217
12. Chan C.H., and Loudon K.W. Activity of tea tree oil on methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 39 3 (1998) 244-245
13. Caelli M., Porteous J., Carson C.F., Heller R., and Riley T.V. Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect 46 3 (2000) 236-237
14. Dryden M.S., Dailly S., and Crouch M. A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect 56 4 (2004) 283-286
15. Hammer K.A., Dry L., Johnson M., Michalak E.M., Carson C.F., and Riley T.V. Susceptibility of oral bacteria to Melaleuca alternifolia (tea tree) oil in vitro. Oral Microbiol Immunol 18 6 (2003) 389-392
16. Schnitzler P., Schön K., and Reichling J. Antiviral activity of Australian tea tree oil against herpes simplex virus in cell culture. Pharmazie 56 4 (2001) 343-347
17. Carson C.F., Ashton L., Dry L., Smith D.W., and Riley T.V. Melaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis. J Antimicrob Chemother 48 3 (2001) 450-451
18. Hammer K.A., Carson C.F., and Riley T.V. Antifungal activity of the components of Melaleuca alternifolia (tea tree) oil. J Appl Microbiol 95 4 (2003) 853-860
19. Oliva B., Piccirilli E., Ceddia T., Pontieri E., Aureli P., and Ferrini A.M. Antimycotic activity of Melaleuca alternifolia essential oil and its major components. Lett Appl Microbiol 37 2 (2003) 185-187
20. Hammer K.A., Carson C.F., and Riley T.V. Antifungal effects of Melaleuca alternifolia (tea tree) oil and its components on Candida albicans, Candida glabrata and Saccharomyces cerevisiae. J Antimicrob Chemother 53 6 (2004) 1081-1085
21. Jandourek A., Vaishampayan J.K., and Vazquez J.A. Efficacy of melaleuca oral solution for the treatment of fluconazole refractory oral candidiasis in AIDS patients. AIDS 12 9 (1998) 1033-1037
22. Vazquez J.A., and Zawawi A.A. Efficacy of alcohol-based and alcohol-free melaleuca oral solution for the treatment of fluconazole-refractory oral candidiasis in patients with AIDS. HIV Clin Trials 3 5 (2002) 379-385
23. Mondello F., De Bernardis F., Girolamo A., Salvatore G., and Cassone A. In vitro and in vivo activity of tea tree oil against azole-susceptible and-resistant human pathogenic yeasts. J Antimicrob Chemother 51 5 (2003) 1223-1229
24. Soukoulis S., and Hirsch R. The effects of a tea tree oil-containing gel on plaque and chronic gingivitis. Aust Dent J 49 2 (2004) 78-83
25. Donnelly S.M., Sullivan D.J., Shanley D.B., and Coleman D.C. Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences. Microbiology 145 8 (1999) 1871-1882
26. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved Standard, January 1997, M7-A4, vol. 17(2).
27. International Organization for Standardization. ISO 4730 Oil of Melaleuca, Terpinen-4-ol type (Tea Tree Oil), 1996. Geneva: International Organization for Standardization.
28. Pelletier R., Loranger L., Marcotte H., and de Carolis E. Voriconazole and fluconazole suceptibility of Candida isolates. J Med Microbiol 51 6 (2002) 479-483
29. Redding S.W., Dahiya M.C., Kirkpatrick W.R., Coco B.J., Patterson T.F., Fothergill A.W., et al. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97 1 (2004) 47-52
30. Chryssanthou E., Cherif H., Petrini B., Kalin M., and Bjorkholm M. Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies. Scand J Infect Dis 36 11-12 (2004) 855-859
31. Krcmery V., and Barnes A.J. Non-albicans Candida spp causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 50 4 (2002) 243-260
32. Groll A.H., and Walsh T.J. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Invest Drugs 10 8 (2001) 1545-1558
33. Banes-Marshall L., Cawley P., and Phillips C.A. In vitro activity of Melaleuca alternifolia (tea tree) oil against bacterial and Candida spp. isolates from clinical specimens. Br J Biomed Sci 58 3 (2001) 139-145
34. Jobbins J., Bagg J., Parsons K., Finlay I., Addy M., and Newcombe R.G. Oral carriage of yeasts, coliforms and staphylococci in patients with advanced malignant disease. J Oral Pathol Med 21 7 (1992) 305-308
35. Ramage G., and López-Ribot J.L. Fungal biofilms and drug resistance. In: San Blas G., and Calderone R.A. (Eds). Pathogenic fungi: host interactions and emerging strategies for control (2004), Horizon Scientific Press, Norwich Chapter 11
36. Carson C.F., Riley T.V., and Cookson B.D. Efficacy and safety of tea tree oil as a topical antimicrobial agent. J Hosp Infect 40 3 (1998) 175-178
37. Groppo F.C., Ramacciato J.C., Simoes R.P., Florio F.M., and Sartoratto A. Antimicrobial activity of garlic, tea tree oil, and chlorhexidine against oral microorganisms. Int Dent J 52 6 (2002) 433-437